

Commonly Requested Compounding Ideas for Autoimmune Disorders

(Commonly Requested Formulas for Patients with Multiple Sclerosis (MS)

| | |
|----------------------|--|
| PCCA Formula # 7992 | Dalfampridine (4-Aminopyridine) 5 mg Capsules Size #3 |
| PCCA Formula # 7994 | Dalfampridine (4-Aminopyridine) 5 mg Slow Release Capsules Size #1 ¹ |
| PCCA Formula # 12586 | Naltrexone HCl 1.5 mg Capsules Size #3 (LoxOral [®]) ^{2,3,4} |
| PCCA Formula # 12584 | Naltrexone HCl 4.5 mg Capsules Size #3 (LoxOral [®]) ^{2,3,4} |
| PCCA Formula # 13388 | Naltrexone HCl 1.5 mg/Dalfampridine (4-Aminopyridine) 5 mg Capsules Size #1 ^{2,3,4} |
| PCCA Formula # 11686 | Biotin 100 mg Capsules Size #3 (LoxOral [®]) ^{5,6,7} |

(Commonly Requested Formulas for Patients with Amyotrophic Lateral Sclerosis (ALS)

| | |
|----------------------|--|
| PCCA Formula # 12586 | Naltrexone HCl 1.5 mg Capsules Size #3 (LoxOral [®]) |
| PCCA Formula # 12584 | Naltrexone HCl 4.5 mg Capsules Size #3 (LoxOral [®]) |
| PCCA Formula # 12484 | Glutathione 20% (W/W) Topical Lipoderm ^{®8} |
| PCCA Formula # 8866 | Glutathione 500mg Base MBK [™] Suppository (Pink Mold) ⁸ |
| PCCA Formula # 11866 | Glutathione 6% Nasal Spray ⁸ |
| PCCA Formula # 11119 | Vitamin E 200 U/Gm Vaginal Gel (MucoLox [™] /VersaBase [®]) ^{59,60,61} |
| PCCA Formula # 8991 | Vitamin E 400 IU Base MBK [™] Vaginal Suppository (Large Shell Mold) ^{59,60,61} |
| PCCA Formula # 8990 | Vitamin E 200 IU Base MBK [™] Vaginal Suppository (Large Shell Mold) ^{59,60,61} |

Commonly Requested Formula for Patients with ALS with Sialorrhea/Excessive Salivation

| | |
|----------------------|--|
| PCCA Formula # 9881 | Atropine Sulfate 1% Sublingual Oral Drops PF ⁹ |
| PCCA Formula # 8537 | Scopolamine 0.25mg/0.1 mL Topical Lipoderm ^{®9,10} |
| PCCA Formula # 8514 | Glycopyrrolate 0.1mg/0.25 mL Topical Lipoderm ^{®9} |
| PCCA Formula # 13536 | Tropicamide 1 mg Troche (NataTroche [®]) ^{11,12,13} |

Commonly Requested Formulas for Patients with ALS with Spasticity


| | |
|----------------------|--|
| PCCA Formula # 12778 | Guaifenesin 15%/Baclofen 2%/Ketoprofen 10% Topical Lipoderm ActiveMax [®] |
| PCCA Formula # 13362 | Magnesium Chloride Hexahydrate 10%/Guaifenesin 10% Topical Gel (PermE8 [®] Anhydrous) |


Commonly Requested Formulas for Patients with Hashimoto's Disease

Levothyroxine/Liothyronine (T4/T3) customized combination oral capsules (See the PCCA formulation database for various combinations available in slow release or immediate release oral capsules)

| | |
|----------------------|--|
| PCCA Formula # 12586 | Naltrexone HCl 1.5 mg Capsules Size #3 (LoxOral [®]) |
| PCCA Formula # 12584 | Naltrexone HCl 4.5 mg Capsules Size #3 (LoxOral [®]) |

Commonly Requested Formulas for Patients with Parkinson's Disease

| | |
|----------------------|--|
| PCCA Formula # 11256 | Carbidopa 1.25 mg/mL/Levodopa 5 mg/mL Oral Suspension (SuspendIt [®]) <i>Carbidopa and levodopa is a combination medicine used to treat symptoms of Parkinson's disease, such as muscle stiffness, tremors, spasms and poor muscle control. Parkinson's disease may be caused by low levels of a chemical called dopamine in the brain.</i> |
| PCCA Formula # 13309 | Glutathione 20% Topical Gel (PermE8 [®] Anhydrous) ^{14,15,16,17} |
| PCCA Formula # 13114 | Glutathione 200 mg Troche (NataTroche [®]) ^{14,15,16,17} |
| PCCA Formula # 11866 | Glutathione 6% Nasal Spray ^{14,15,16,17} |
| PCCA Formula # 12739 | Glutathione 200 mg Rapid Dissolve Tablet (RDT-Plus [™]) ^{14,15,16,17} |
| PCCA Formula # 12238 | Oxytocin 10 Units/0.1 mL to 100 Units/0.1 mL Nasal Spray/Sublingual Suspension (MucoLox [™]) (FormulaPlus [™]  BUD Bracketed Study) ^{18,19,20,21} |

PCCA Formula # 12518 Methylcobalamin 2mg/mL Nasal Spray (Synapsin®) (FormulaPlus™  BUD Study)^{22,23,24,25,26,27,28}
For more information, see PCCA Document #99620, Compounding with Synapsin – Consultant’s Corner Article by Don Bottoni.

Commonly Requested Formula for Patients with Parkinson’s Disease Who Need Assistance with Bladder Control


PCCA Formula # 13073 Oxybutynin Chloride 8% Topical Lipoderm®^{29,30}

Commonly Requested Formulas for Patients with Parkinson’s Disease with Pain/Neuropathy/Muscle Stiffness

PCCA Formula # 10056 Guaifenesin 10%/Magnesium Sulfate Heptahydrate 10% Topical Lipoderm®

PCCA Formula # 11091 Ketamine HCl 10%/Baclofen 2%/Cyclobenzaprine HCl 2%/Gabapentin 6%/Lidocaine 5% Topical Lipoderm ActiveMax®

Commonly Requested Formula for Patients with Parkinson’s Disease with Anxiety

PCCA Formula # 10863 Lorazepam 5 mg/Gm Topical Lipoderm® (FormulaPlus™  BUD Study)

Commonly Requested Formulas for Patients with Lupus

Commonly Requested Formula for Patients with Lupus with Raynaud’s Syndrome

PCCA Formula # 10844 Pentoxifylline 3%/Nifedipine 3% Topical Lipoderm®

PCCA Formula # 13276 Tadalafil 1mg/Gm Topical Lipoderm®^{31,32,33,34,35,36}

PCCA Formula # 12883 Nifedipine 0.2%/Arginine HCl 6% Topical Lipoderm®

Commonly Requested Formulas for Patients with Lupus with Extreme Fatigue

PCCA Formula # 5624 Caffeine 100 mg Sorbitol Lollipop Base^{37,38}

PCCA Formula # 11231 Caffeine 5 mg/mL Oral Suspension (SuspendIt®)^{37,38}

Commonly Requested Formulas for Patients with Lupus with Dry Eyes

PCCA Formula # 12476 Naltrexone HCl 0.2% Ophthalmic Solution

PCCA Formula # 12365 Naltrexone HCl 1% Ophthalmic Ointment

PCCA Formula # 13534 Cyclosporin 0.1% Ophthalmic Emulsion (PF)

PCCA Formula # 13338 Tacrolimus 0.03% Oil Ophthalmic Solution

PCCA Formula # 12341 Testosterone 3% Ophthalmic Ointment

Commonly Requested Formula for Patients with Lupus with Dry Mouth

PCCA Formula # 11151 Pilocarpine HCl 10 mg/mL Oral Drops (MucoLox™) (FormulaPlus™  BUD Study)

PCCA Formula # 11768 Xylitol 10% /Olive Oil 2%/Beta Glucan Oral Rinse (MucoLox™)

PCCA Formula # 11150 Electrolyte Saliva Gel (MucoLox™)

PCCA Formula # 11149 Artificial Saliva Gel (MucoLox™)

Commonly Requested Formula for Patients with Lupus Who Bruise Easily

PCCA Formula # 5723 Ascorbic Acid 20%/Phytonadione 1%/Vitamin E 5 IU/Gm Topical Cream

Commonly Requested Formula for Male Patients with Lupus

PCCA Formula # 12674 Testosterone 0.5% to 20% Topical Gel (Atrevis Hydrogel®) (FormulaPlus™  BUD Bracketed Study)⁷²

Commonly Requested Formulas for Patients with Crohn’s Disease/Ulcerative Colitis

PCCA Formula # 11585 Budesonide 2 mg/30 mL Retention Enema (MucoLox™)^{39,40,41}

PCCA Formula # 12053 Sodium Butyrate 100 mM Enema (MucoLox™)^{42,43,44,45,46,47,49}


| | |
|----------------------|---|
| PCCA Formula # 12699 | Mesalamine 4 Gm/60 mL/Budesonide 4 mg/60 mL Retention Enema (MucoLox™) ^{39,40,41,42,43,44,45,46,47,49} |
| PCCA Formula # 11373 | Tacrolimus 4 mg/60 mL Rectal Enema (MucoLox™) ^{47,48,49} |
| PCCA Formula # 11933 | Tacrolimus 0.1% Rectal Gel (MucoLox™/VersaBase®) ^{50,51} |
| PCCA Formula # 12586 | Naltrexone HCl 1.5 mg Capsules Size #3 (LoxOral®) ^{52,53,54,55} |
| PCCA Formula # 12584 | Naltrexone HCl 4.5 mg Capsules Size #3 (LoxOral®) ^{52,53,54,55} |

Commonly Requested Formulas for Male Patients with Crohn's Disease/Ulcerative Colitis

Dispense compounded enema preparations in a 2 oz Thin Wall (Douche/Enema) White Opaque Polyethylene Bottle(s) .(PCCA #35-1668) with Enema Cap (PCCA #35-1534

| | |
|----------------------|------------------------------------|
| PCCA Formula # 12273 | Retention Enema Vehicle (MucoLox™) |
| PCCA Formula # 11079 | Poloxamer Retention Enema |
| PCCA Formula # 4297 | Retention Enema Vehicle |






Commonly Requested Formulas for Patients with Sjögren's Syndrome

| | |
|----------------------|--|
| PCCA Formula # 12913 | Xylitol 10%/Sodium Fluoride 0.05%/Malic Acid Oral Spray (MucoLox™) |
| PCCA Formula # 12476 | Naltrexone HCl 0.2% Ophthalmic Solution |
| PCCA Formula # 12365 | Naltrexone HCl 1% Ophthalmic Ointment |
| PCCA Formula # 13534 | Cyclosporin 0.1% Ophthalmic Emulsion (PF) |
| PCCA Formula # 12229 | Estriol 0.025% to 1% Topical/Vaginal Cream (VersaBase®) (FormulaPlus™  BUD Bracketed Study) |


Commonly Requested Compounding Vehicles for Autoimmune Patients with Difficulty Swallowing

- . **PCCA SuspendIt® (PCCA #30-4825):** For preparing oral liquid for patients who cannot swallow capsules or tablets
- . **PCCA Lipoderm® (PCCA #30-3338) or PCCA PermE8® Anhydrous Gel (PCCA #30-5038):** For delivering drugs through the skin with a permeation enhancing base for patients who cannot swallow
- . **PCCA MBK™ Fatty Acid (PCCA #30-1056) Suppositories:** For giving medications rectally for patients who cannot swallow

Commonly Requested Formulas for Female Patients with Autoimmune Disorders

| | |
|----------------------|--|
| PCCA Formula # 8905 | Estriol 2 mg/0.1 mL Topical Cream ^{67,69} |
| PCCA Formula # 12229 | Estriol 0.025% to 1% Vaginal Cream (VersaBase®) (FormulaPlus™  BUD Bracketed Study) ^{67,69} |
| PCCA Formula # 13310 | Estriol/Estradiol [80%/20%] 0.25 mg/Gm to 5 mg/Gm/Testosterone 0.5 mg/Gm to 10 mg/Gm/Progesterone 10 mg/Gm to 125 mg/Gm Topical Cream (VersaBase®) (FormulaPlus™  BUD Bracketed Study) ^{62,63,64,65,66,71} |
| PCCA Formula # 12116 | Estriol/Estradiol [50%/50%] 0.25 mg/0.5 Gm to 1 mg/0.5 Gm Topical Cream (VersaBase®) (FormulaPlus™  BUD Bracketed Study) ^{62,63,64,65,66,71} |
| PCCA Formula # 12114 | Progesterone 10 mg/Gm to 100 mg/Gm Topical Cream (VersaBase®) (FormulaPlus™  BUD Bracketed Study) |
| PCCA Formula # 11641 | Testosterone 0.1% to 10% Topical Cream (VersaBase®) (FormulaPlus™  BUD Bracketed Study) ^{66,68} |

Commonly Requested Formulas for Female Patients with Autoimmune Disorders and Sexual Dysfunction

| | |
|----------------------|--|
| PCCA Formula # 11641 | Testosterone 0.1% to 10% Topical Cream (VersaBase®) (FormulaPlus™  BUD Bracketed Study) ⁵⁶ |
| PCCA Formula # 10879 | Papaverine HCl 0.1%/Arginine 6% Topical Lipoderm® |
| PCCA Formula # 11948 | Sildenafil 1%/Testosterone 0.1% Topical Gel (MucoLox™) |

Commonly Requested Formulas for Male Patients with Autoimmune Disorders and Erectile Dysfunction

| | |
|----------------------|--|
| PCCA Formula # 13267 | Tadalafil 10 mg/Apomorphine HCl 2 mg Troche (NataTroche®) ^{57,58} |
|----------------------|--|

| | |
|----------------------|--|
| PCCA Formula # 13265 | Tadalafil 7.5 mg Capsules Size #3 (LoxOral®) ^{57,58} |
| PCCA Formula # 13259 | Tadalafil 6 mg Troche (NataTroche®) ^{57,58} |
| PCCA Formula # 13130 | Sildenafil 20 mg Troche (NataTroche®) (Tablet Triturate 200 mg Mold) ⁵⁸ |

The formulas and/or statements listed are provided for educational purposes only. They are compounding ideas that have commonly been requested by physicians, and have not been evaluated by the Food and Drug Administration. Formulas and/or material listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.

REFERENCES:

1. Chwieduk, C. M., & Keating, G. M. (2010). Dalfampridine Extended Release: in Multiple Sclerosis. *CNS Drugs*, 24(10), 883-891. <https://doi.org/10.2165/11205910-000000000-00000>
2. Ludwig, M. D., Zagon, I. S., & McLaughlin, P. J. (2017). Featured Article: Serum [Met⁵]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone. *Experimental Biology and Medicine (Maywood, N.J.)*, 242(15), 1524–1533. <https://doi.org/10.1177/2055217316672242>
3. Ludwig, M. D., Turel, A. P., Zagon, I. S., & McLaughlin, P. J. (2016). Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, 2, 2055217316672242. <https://doi.org/10.1177/2055217316672242>
4. Rahn, K.A., McLaughlin, P.J., & Zagon, I.S. (2011). Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis. *Brain Research*, 1381, 243-253. doi: 10.1016/j.brainres.2011.01.036
5. Guillevin, C., Agius, P., Naudin, M., Herpe, G., Ragot, S., Maubeuge, N., Philippe Neau, J., & Guillevin, R. (2019). ¹H-³¹P magnetic resonance spectroscopy: effect of biotin in multiple sclerosis. *Annals of Clinical and Translational Neurology*, 6(7), 1332–1337. <https://doi.org/10.1002/acn3.50825>
6. Siddiqui, U., Egnor, E., & Sloane, J. A. (2017). Biotin supplementation in MS clinically valuable but can alter multiple blood test results. *Multiple Sclerosis Journal*, 23(4), 619-620. doi: 10.1177/1352458516680751
7. Sedel, F., Bernard, D., Mock, D. M., & Tourbah, A. (2016). Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. *Neuropharmacology*, 110, 644-653. doi: 10.1016/j.neuropharm.2015.08.028
8. Wang, Z., Bai, Z., Qin, X., & Cheng, Y. (2019). Aberrations in Oxidative Stress Markers in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. *Oxidative Medicine and Cellular Longevity*, 2019, 1712323. <https://doi.org/10.1155/2019/1712323>
9. Banfi, P., Ticozzi, N., Lax, A., Guidugli, G. A., Nicolini, A., & Silani, V. (2015). A review of options for treating sialorrhea in amyotrophic lateral sclerosis. *Respiratory Care*, 60(3), 446-454. <https://doi.org/10.4187/respcare.02856>
10. Mato, A., Limeres, J., Tomás, I., Muñoz, M., Abuín, C., Feijoo, J. F., & Diz, P. (2010). Management of drooling in disabled patients with scopolamine patches. *British Journal of Clinical Pharmacology*, 69(6), 684–688. <https://doi.org/10.1111/j.1365-2125.2010.03659.x>
11. Farber, N. M., Perez-Lloret, S., & Gamzu, E. R. (2015). Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson's disease. *Current Topics in Medicinal Chemistry*, 15(10), 939-954. <https://doi.org/10.2174/156802661510150328224130>
12. Lloret, S. P., Nano, G., Carrosella, A., Gamzu, E., & Merello, M. (2011). A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. *Journal of the Neurological Sciences*, 310(1-2), 248-250. <https://doi.org/10.1016/j.jns.2011.05.021>
13. Kilic, O., Ozturk, M., & Ata Gozcelioglu, E. (2017). Tropicamide ophthalmic solution reduces clozapine-induced sialorrhea: a case report. *Psychiatry and Clinical Psychopharmacology*, 27(4), 431-434. doi:10.1080/24750573.2017.1347601
14. Wei, Z., Li, X., Li, X., Liu, Q., & Cheng, Y. (2018). Oxidative Stress in Parkinson's Disease: A Systematic Review and Meta-Analysis. *Frontiers in Molecular Neuroscience*, 11, 236. <https://doi.org/10.3389/fnmol.2018.00236>
15. Franceschelli, S., Lanuti, P., Ferrone, A., Gatta, D., Speranza, L., Pesce, M., Grilli, A., Cacciatore, I., Ricciotti, E., Di Stefano, A., Miscia, S., Felaco, M., & Patruno, A. (2019). Modulation of Apoptotic Cell Death and Neuroprotective Effects of Glutathione-L-Dopa Codrug Against H₂O₂-Induced Cellular Toxicity. *Antioxidants (Basel, Switzerland)*, 8(8), 319. <https://doi.org/10.3390/antiox8080319>

16. Monti, D. A., Zabrecky, G., Kremens, D., Liang, T. W., Wintering, N. A., Bazzan, A. J., ... & Newberg, A. B. (2019). N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease. *Clinical Pharmacology & Therapeutics*, 106(4), 884-890. <https://doi.org/10.1002/cpt.1548>
17. Wei, H.J., Du, M., & Bai, H.Y. (2019). [Correlations of Melatonin and Glutathione Levels with Oxidative Stress Mechanism in Parkinson's Disease]. *Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae*, 41(2), 183-187. doi: 10.3881/j.issn.1000-503X.10775
18. Erbaş, O., Oltulu, F., & Taşkıran, D. (2012). Amelioration of rotenone-induced dopaminergic cell death in the striatum by oxytocin treatment. *Peptides*, 38(2), 312- 317. doi:10.1016/j.peptides.2012.05.026
19. Gamal-Eltrabily, M., & Manzano-García, A. (2018). Role of central oxytocin and dopamine systems in nociception and their possible interactions: suggested hypotheses. *Reviews in the Neurosciences*, 29(4), 377-386. <https://doi.org/10.1515/revneuro-2017-0068>
20. Erbas, O., Oltulu, F., & Taskiran, D. (2013). Suppression of exaggerated neuronal oscillations by oxytocin in a rat model of Parkinson's disease. *General Physiology and Biophysics*, 32(4), 517-525. https://doi.org/10.4149/gpb_2013055
21. Purba, J. S., Hofman, M. A., & Swaab, D. F. (1994). Decreased number of oxytocin-immunoreactive neurons in the paraventricular nucleus of the hypothalamus in Parkinson's disease. *Neurology*, 44(1), 84-84. <https://doi.org/10.1212/WNL.44.1.84>
22. Ardah, M. T., Paleologou, K. E., Lv, G., Menon, S. A., Abul Khair, S. B., Lu, J. H., Safieh-Garabedian, B., Al-Hayani, A. A., Eliezer, D., Li, M., & El-Agnaf, O. M. (2015). Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. *Neurobiology of Disease*, 74, 89-101. <https://doi.org/10.1016/j.nbd.2014.11.007>
23. He, Y. B., Liu, Y. L., & Chen, Y. M. (2017). Comment on "A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson's Disease". *Oxidative Medicine and Cellular Longevity*, 2017, 7623954. <https://doi.org/10.1155/2017/7623954>
24. Larrick, J. W., & Mendelsohn, A. R. (2019). Roads to the fountain of youth? Rejuvenating intestinal stem cells. *Rejuvenation Research*, 22(4), 342-347. <https://doi.org/10.1089/rej.2019.2251>
25. Xu, L., Chen, W. F., & Wong, M. S. (2009). Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway. *British Journal of Pharmacology*, 158(3), 738-748. <https://doi.org/10.1111/j.1476-5381.2009.00361.x>
26. Schöndorf, D. C., Ivanyuk, D., Baden, P., Sanchez-Martinez, A., De Cicco, S., Yu, C., ... & Nestel, S. (2018). The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's Disease. *Cell Reports*, 23(10), 2976-2988. <https://doi.org/10.1016/j.celrep.2018.05.009>
27. Joo, S. S., Yoo, Y. M., Ahn, B. W., Nam, S. Y., Kim, Y. B., Hwang, K. W., & Lee, D. I. (2008). Prevention of inflammation-mediated neurotoxicity by Rg3 and its role in microglial activation. *Biological and Pharmaceutical Bulletin*, 31(7), 1392-1396. <https://doi.org/10.1248/bpb.31.1392>
28. Chi, Y., & Sauve, A. A. (2013). Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. *Current Opinion in Clinical Nutrition & Metabolic Care*, 16(6), 657-661. <https://doi.org/10.1097/MCO.0b013e32836510c0>
29. Cohn, J. A., Brown, E. T., Reynolds, W. S., Kaufman, M. R., Milam, D. F., & Dmochowski, R. R. (2016). An update on the use of transdermal oxybutynin in the management of overactive bladder disorder. *Therapeutic Advances in Urology*, 8(2), 83-90. <https://doi.org/10.1177/1756287215626312>
30. Mostile, G., & Jankovic, J. (2009). Treatment of dysautonomia associated with Parkinson's disease. *Parkinsonism & Related Disorders*, 15(3), S224-S232. [https://doi.org/10.1016/S1353-8020\(09\)70820-X](https://doi.org/10.1016/S1353-8020(09)70820-X)
31. Kamata, Y., & Minota, S. (2014). Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon. *Rheumatology International*, 34(11), 1623-1626. <https://doi.org/10.1007/s00296-014-3025-z>
32. Hamishehkar, H., Khoshbakht, M., Jouyban, A., & Ghanbarzadeh, S. (2015). The Relationship between Solubility and Transdermal Absorption of Tadalafil. *Advanced Pharmaceutical Bulletin*, 5(3), 411-417. <https://doi.org/10.15171/apb.2015.056>
33. Shenoy, P. D., Kumar, S., Jha, L. K., Choudhary, S. K., Singh, U., Misra, R., & Agarwal, V. (2010). Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. *Rheumatology*, 49(12), 2420-2428. <https://doi.org/10.1093/rheumatology/keq291>
34. Baek, J. S., Pham, C. V., Myung, C. S., & Cho, C. W. (2015). Tadalafil-loaded nanostructured lipid carriers using permeation enhancers. *International Journal of Pharmaceutics*, 495(2), 701-709. <https://doi.org/10.1016/j.ijpharm.2015.09.054>
35. Baumhaekel, M., Scheffler, P., & Boehm, M. (2005). Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. *Microvascular Research*, 69(3), 178-179. <https://doi.org/10.1016/j.mvr.2005.03.001>
36. Baek, J. S., & Cho, C. W. (2016). Transdermal delivery of tadalafil using a novel formulation. *Drug Delivery*, 23(5), 1571-1577. <https://doi.org/10.3109/10717544.2015.1077291>
37. Iris, M., Tsou, P. S., & Sawalha, A. H. (2018). Caffeine inhibits STAT1 signaling and downregulates inflammatory pathways involved in autoimmunity. *Clinical Immunology*, 192, 68-77. <https://doi.org/10.1016/j.clim.2018.04.008>

38. Al Reef, T., & Ghanem, E. (2018). Caffeine: Well-known as psychotropic substance, but little as immunomodulator. *Immunobiology*, 223(12), 818-825. <https://doi.org/10.1016/j.imbio.2018.08.011>
39. Gross, V., Bar-Meir, S., Lavy, A., Mickisch, O., Tulassay, Z., Pronai, L., ... & Faszczyk, M. (2006). Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. *Alimentary Pharmacology & Therapeutics*, 23(2), 303-312. <https://doi.org/10.1111/j.1365-2036.2006.02743.x>
40. Lindgren, S., Löfberg, R., Bergholm, L., Hellblom, M., Carling, L., Ung, K. A., ... & Persson, T. (2002). Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. *Scandinavian Journal of Gastroenterology*, 37(6), 705-710. <https://doi.org/10.1080/00365520212512>
41. Christophi, G. P., Rengarajan, A., & Ciorba, M. A. (2016). Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. *Clinical and Experimental Gastroenterology*, 9, 125-130. <https://doi.org/10.2147/CEG.S80237>
42. Breuer, R. I., Buto, S. K., Christ, M. L., Bean, J., Vernia, P., Paoluzi, P., ... & Caprilli, R. (1991). Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. *Digestive Diseases and Sciences*, 36(2), 185-187. <https://doi.org/10.1007/BF01300754>
43. Patz, J., Jacobsohn, W. Z., Gottschalk-Sabag, S., Zeides, S., & Braverman, D. Z. (1996). Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas. *American Journal of Gastroenterology*, 91(4), 731-734.
44. Neut, C., Guillemot, F., Gower-Rousseau, C., Biron, N., Cortot, A., & Colombel, J. F. (1995). Treatment of diversion colitis with short-chain fatty acids. Bacteriological study. *Gastroenterologie Clinique et Biologique*, 19(11), 871-875.
45. Scheppach, W., Müller, J. G., Boxberger, F., Dusel, G., Richter, F., Bartram, H. P., ... & Kasper, H. (1997). Histological changes in the colonic mucosa following irrigation with short-chain fatty acids. *European Journal of Gastroenterology & Hepatology*, 9(2), 163-168. <https://doi.org/10.1097/00042737-199702000-00010>
46. Harig, J. M., Soergel, K. H., Komorowski, R. A., & Wood, C. M. (1989). Treatment of diversion colitis with short-chain-fatty acid irrigation. *New England Journal of Medicine*, 320(1), 23-28. doi: 10.1056/NEJM198901053200105
47. Lawrance, I. C. (2011). Topical agents for idiopathic distal colitis and proctitis. *Journal of Gastroenterology and Hepatology*, 26(1), 36-43. <https://doi.org/10.1111/j.1440-1746.2010.06497.x>
48. van Dieren, J. M., van Bodegraven, A. A., Kuipers, E. J., Bakker, E. N., Poen, A. C., van Dekken, H., ... & van der Woude, J. C. (2009). Local application of tacrolimus in distal colitis: feasible and safe. *Inflammatory Bowel Diseases*, 15(2), 193-198. doi: 10.1002/ibd.20644
49. Lawrance I. C. (2010). Novel topical therapies for distal colitis. *World Journal of Gastrointestinal Pharmacology and Therapeutics*, 1(5), 87-93. <https://doi.org/10.4292/wjgpt.v1.i5.87>
50. Nanaeva, B. A., Vardanyan, A. V., & Khalif, I. L. (2015). Efficiency of tacrolimus therapy for perianal Crohn's disease. *Terapevticheskii arkhiv*, 87(6), 83-87. <https://doi.org/10.17116/terarkh201587683-87>
51. Hart, A. L., Plamondon, S., & Kamm, M. A. (2007). Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. *Inflammatory Bowel Diseases*, 13(3), 245-253. <https://doi.org/10.1002/ibd.20073>
52. Raknes, G., Simonsen, P., & Småbrekke, L. (2018). The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before-and-After Prescription Database Study. *Journal of Crohn's & Colitis*, 12(6), 677-686. <https://doi.org/10.1093/ecco-jcc/jjy008>
53. Parker, C. E., Nguyen, T. M., Segal, D., MacDonald, J. K., & Chande, N. (2018). Low dose naltrexone for induction of remission in Crohn's disease. *The Cochrane Database of Systematic Reviews*, 4(4), CD010410. <https://doi.org/10.1002/14651858.CD010410.pub3>
54. Smith, J. P., Field, D., Bingaman, S. I., Evans, R., & Mauger, D. T. (2013). Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. *Journal of Clinical Gastroenterology*, 47(4), 339-345. <https://doi.org/10.1097/MCG.0b013e3182702f2b>
55. Smith, J. P., Bingaman, S. I., Ruggiero, F., Mauger, D. T., Mukherjee, A., McGovern, C. O., & Zagon, I. S. (2011). Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. *Digestive Diseases and Sciences*, 56(7), 2088-2097. <https://doi.org/10.1007/s10620-011-1653-7>
56. Ganesan, K., Habboush, Y., & Sultan, S. (2018). Transdermal Testosterone in Female Hypoactive Sexual Desire Disorder: A Rapid Qualitative Systematic Review Using Grading of Recommendations Assessment, Development and Evaluation. *Cureus*, 10(3), e2401. <https://doi.org/10.7759/cureus.2401>
57. Lombardi, G., Macchiarella, A., & Del Popolo, G. (2010). Efficacy and Safety of Tadalafil for Erectile Dysfunction in Patients with Multiple Sclerosis. *The Journal of Sexual Medicine*, 7(6), 2192-2000. <https://doi.org/doi:10.1111/j.1743-6109.2010.01797.x>
58. Picillo, M., Palladino, R., Erro, R., Colosimo, C., Marconi, R., Antonini, A., ... & PRIAMO study group. (2019). The PRIAMO study: active sexual life is associated with better motor and non-motor outcomes in men with early Parkinson's disease. *European Journal of Neurology*, 26(10), 1327-1333. <https://doi.org/10.1111/ene.13983>
59. Chiricosta, L., Gugliandolo, A., Tardiolo, G., Bramanti, P., & Mazzoni, E. (2019). Transcriptomic Analysis of MAPK Signaling in NSC-34 Motor Neurons Treated with Vitamin E. *Nutrients*, 11(5), 1081. <https://doi.org/10.3390/nu11051081>

60. Freedman, D. M., Kuncl, R. W., Weinstein, S. J., Malila, N., Virtamo, J., & Albanes, D. (2013). Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration*, 14(4), 246–251. <https://doi.org/10.3109/21678421.2012.745570>
61. von Grabowiecki, Y., Licona, C., Palamiuc, L., Abreu, P., Vidimar, V., Coowar, D., ... & Gaiddon, C. (2015). Regulation of a Notch3-Hes1 pathway and protective effect by a tocopherol-omega alkanol chain derivative in muscle atrophy. *Journal of Pharmacology and Experimental Therapeutics*, 352(1), 23–32. <https://doi.org/10.1124/jpet.114.216879>
62. Avila, M., Bansal, A., Culbertson, J., & Peiris, A. N. (2018). The role of sex hormones in multiple sclerosis. *European Neurology*, 80(1-2), 93–99. doi: 10.1159/000494262
63. Ysrraelit, M. C., & Correale, J. (2019). Impact of sex hormones on immune function and multiple sclerosis development. *Immunology*, 156(1), 9–22. <https://doi.org/10.1111/imm.13004>
64. MacKenzie-Graham, A., Brook, J., Kurth, F., Itoh, Y., Meyer, C., Montag, M. J., Wang, H. J., Elashoff, R., & Voskuhl, R. R. (2018). Estriol-mediated neuroprotection in multiple sclerosis localized by voxel-based morphometry. *Brain and Behavior*, 8(9), e01086. <https://doi.org/10.1002/brb3.1086>
65. Assad, S., Khan, H. H., Ghazanfar, H., Khan, Z. H., Mansoor, S., Rahman, M. A., Khan, G. H., Zafar, B., Tariq, U., & Malik, S. A. (2017). Role of Sex Hormone Levels and Psychological Stress in the Pathogenesis of Autoimmune Diseases. *Cureus*, 9(6), e1315. <https://doi.org/10.7759/cureus.1315>
66. Gubbels Bupp, M. R., & Jorgensen, T. N. (2018). Androgen-Induced Immunosuppression. *Frontiers in Immunology*, 9, 794. <https://doi.org/10.3389/fimmu.2018.00794>
67. Itoh, N., Kim, R., Peng, M., DiFilippo, E., Johnsonbaugh, H., MacKenzie-Graham, A., & Voskuhl, R. R. (2017). Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis. *Journal of Neuroimmunology*, 304, 63–71. <https://doi.org/10.1016/j.jneuroim.2016.09.017>
68. Tavakol, S., Shakibapour, S., & Bidgoli, S. A. (2018). The level of testosterone, vitamin D, and irregular menstruation more important than omega-3 in non-symptomatic women will define the fate of multiple sclerosis in future. *Molecular Neurobiology*, 55(1), 462–469. <https://doi.org/10.1007/s12035-016-0325-1>
69. Ali, E. S., Mangold, C., & Peiris, A. N. (2017). Estriol: emerging clinical benefits. *Menopause*, 24(9), 1081–1085. <https://doi.org/10.1097/GME.0000000000000855>
70. Khan, M., Ullah, R., Rehman, S. U., Shah, S. A., Saeed, K., Muhammad, T., Park, H. Y., Jo, M. H., Choe, K., Rutten, B., & Kim, M. O. (2019). 17β-Estradiol Modulates SIRT1 and Halts Oxidative Stress-Mediated Cognitive Impairment in a Male Aging Mouse Model. *Cells*, 8(8), 928. <https://doi.org/10.3390/cells8080928>
71. Labandeira-Garcia, J. L., Rodriguez-Perez, A. I., Valenzuela, R., Costa-Besada, M. A., & Guerra, M. J. (2016). Menopause and Parkinson's disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration. *Frontiers in Neuroendocrinology*, 43, 44–59. <https://doi.org/10.1016/j.yfrne.2016.09.003>
72. Pakpoor, J., Goldacre, R., & Goldacre, M. J. (2018). Associations between clinically diagnosed testicular hypofunction and systemic lupus erythematosus: a record linkage study. *Clinical Rheumatology*, 37(2), 559–562. <https://doi.org/10.1007/s10067-017-3873-5>